Clinical Trial Update: Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)

View source ↗

Summary

This entry notes a recruiting clinical study in multiple sclerosis to predict disease activity and rebound risk in patients treated with S1P receptor modulators…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Sphingosine-1-phosphate receptor modulator (S1PRM)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Multiple Sclerosis | Status: RECRUITING